All In Biotech

Drug Trial Radar · NCT00125593

Study of Heart and Renal Protection

Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 9,438 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,438

Actual

Start

Jun 2003

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC; Schering-Plough; National Health and Medical Research Council, Australia; British Heart Foundation; Medical Research Council
First posted
Aug 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for revascularization procedures in patients with chronic kidney disease (CKD). It also aimed to assess whether lowering LDL cholesterol reduced the rate of loss of renal function in people with CKD who had not commenced dialysis treatment.

Conditions

  • Kidney Disease, Chronic

Interventions

  • Simvastatin 20 mgDrug

    Once daily

  • Ezetimibe 10mgDrug

    Once daily

  • PlaceboDrug

    Once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Key Outcome as Per Statistical Analysis Plan = Major Atherosclerotic Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to PlaceboTime frame: Median follow-up 4.9 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.